Economic Study Links GLP-1 Drug Use to 17% Drop in Worker Sick Leave

The corporate debate over GLP-1 medications has largely centered on a single, intimidating metric: the upfront cost to employer health plans. Because drugs like Ozempic and Wegovy carry steep monthly price tags, many companies view them strictly as budget-breaking expenses, leading to a wave of coverage restrictions. But new economic data suggests this ledger is missing a massive, hidden variable. When employees manage chronic metabolic conditions effectively, they miss significantly less work. By focusing entirely on pharmacy expenditures, employers may be overlooking the profound financial toll of absenteeism and diminished workplace productivity.[1][4]

A working paper published this month by the National Bureau of Economic Research (NBER) provides some of the first large-scale, empirical evidence quantifying this effect. Conducted by researchers from the University of Copenhagen, the University of Chicago, Duke University, and the Rockwool Foundation, the study sought to measure how GLP-1 receptor agonists impact the labor market. Rather than looking at weight loss or blood sugar levels, the economists looked at timesheets, disability claims, and employment records to see if healthier patients translated into more reliable workers.[2][3]

To isolate the economic impact, the researchers utilized Denmark’s comprehensive national health and employment registries. They identified a cohort of 7,011 patients who began taking Ozempic during the drug’s first 17 months of availability. They then matched this group against a control cohort of 7,011 similar patients who did not initiate treatment until four years later. This staggered adoption allowed the economists to compare the employment trajectories of those actively taking the medication against those who were still waiting, providing a clear window into the drug's real-world impact on workplace attendance.[3][4]

The primary finding was striking: patients actively taking GLP-1 medications experienced a 17.3 percent reduction in long-term sick leave compared to the control group. The researchers defined long-term sick leave as any medically certified, illness-related absence lasting longer than 30 days. Prior to initiating treatment, an average of 5.5 percent of the workers in the study required long-term leave. Following the introduction of the medication, that figure dropped by nearly a full percentage point, a statistically significant decline that progressively widened the longer the patients remained on the therapy.[2][3]

Translating that recovered time into financial terms reveals a substantial macroeconomic benefit. The reduction in missed workdays generated an estimated $866 in annual productivity gains per employed patient. According to the researchers, this equates to roughly 1.3 to 1.5 percent of an individual’s annual labor income. While a single employee missing fewer days might seem like a marginal gain, scaled across a massive corporate workforce or a national economy, the recovered labor hours represent billions of dollars in preserved economic output.[1][4]

The physiological mechanism driving this increased attendance goes far beyond simple weight reduction. GLP-1 medications are known to significantly reduce the risk of major adverse cardiovascular events, including heart attacks and strokes. The Danish study documented parallel reductions in emergency department visits and the use of cardiovascular drugs among the treated cohort. By preventing these acute, catastrophic health events—which almost always necessitate extended medical absences—the medications keep employees out of the hospital and in the workforce.[1][2]

Beyond preventing hospitalizations, the drugs appear to alleviate the daily friction of chronic illness. Physicians note that when patients lose 10 to 15 percent of their body weight, they experience cascading benefits: reduced systemic inflammation, improved mobility, less joint stress, and the alleviation of sleep apnea. These improvements combat what economists call "presenteeism"—the phenomenon where employees show up to work but operate at a fraction of their normal capacity because they feel unwell. A workforce that sleeps better and moves easier is inherently more productive.[4][6]

However, as an evidence pack, the NBER data carries several crucial limitations that complicate its application to the broader public. First, the findings are currently available as a working paper and have not yet undergone formal peer review. Second, the demographic makeup of the Danish cohort was highly specific: approximately 84 percent of the patients in the study had a formal diagnosis of diabetes. Because the cohort was heavily skewed toward diabetic patients, it is difficult to cleanly isolate how much of the absenteeism drop was driven by weight loss alone versus the stabilization of severe blood sugar fluctuations.[2][3]

The most significant hurdle in interpreting the data is the vast structural difference between the Danish and American healthcare systems. Denmark operates a national health insurance plan with heavily subsidized medical care and a highly structured sick leave policy. In the Danish system, employers are required to pay a worker's full salary for the first 30 days of an illness-related absence. If the absence extends beyond 30 days, the government assumes the financial burden of covering the worker's long-term leave.[1][4]

Because the NBER study specifically measured absences lasting longer than 30 days, the bulk of the $866 in annual savings accrued directly to the Danish government, rather than to private employers. A reduction in short-term illness certainly benefits the employer by keeping the worker at their desk, but the massive fiscal relief of avoiding long-term disability claims is absorbed by the state. This dynamic makes it incredibly difficult to map the study's financial conclusions directly onto the American corporate landscape.[1][4]

In the United States, the financial burden of healthcare and sick leave falls squarely on the shoulders of private employers. American companies face higher direct healthcare costs because they receive vastly less government support for medical expenses. When an American worker goes on long-term disability, the employer—or the employer's private insurance carrier—bears the cost. Consequently, while US employers stand to gain immensely from a healthier, more present workforce, they also bear the entirety of the upfront cost of funding the $1,000-a-month GLP-1 prescriptions.[4][5]

This tension has created a standoff in the American labor market. Recent surveys indicate that many large US employers view rising prescription drug costs, particularly the explosion in GLP-1 usage, as the primary driver of higher insurance premiums. In response, a growing number of companies are moving to restrict coverage, implement strict prior authorization requirements, or drop the medications from their formularies entirely. They are prioritizing immediate balance-sheet relief over theoretical, long-term productivity gains.[4][5]

Health economists argue that this short-term cost-cutting could trigger unintended financial consequences. If an employer drops GLP-1 coverage, the immediate pharmacy spend decreases, but the underlying metabolic conditions of the workforce remain untreated. Over time, those untreated conditions manifest as higher rates of cardiovascular disease, increased emergency room utilization, and a surge in the very long-term sick leave documented in the Danish study. The NBER findings suggest that employers may simply be trading a predictable pharmacy expense for unpredictable medical and absenteeism costs.[4][5]

Further complicating the American outlook is the issue of patient adherence. The Danish study noted that an impressive 75 percent of patients remained on the GLP-1 medications long-term, allowing the health benefits to compound over several years. In contrast, data from the United States shows that adherence rates hover between 40 and 60 percent, with many patients abandoning the drugs within the first year due to side effects, supply shortages, or changes in insurance coverage. If workers do not stay on the medication, the projected economic benefits evaporate.[2][5]

Despite these caveats, the NBER working paper marks a fundamental shift in how the medical and economic communities view GLP-1 receptor agonists. The conversation is expanding beyond individual weight loss and clinical trial endpoints to encompass macroeconomic stability. If further research confirms that these medications can systematically reduce workforce absenteeism and lower the burden of disability claims, they may eventually be classified not just as medical treatments, but as vital investments in national economic infrastructure.[2][6]